Recipharm, a contract development and manufacturing organization based in Sweden, has appointed Dr. Hans Lennernäs to the operating board of Recipharm Pharmaceutical Development.

Lennernäs is a professor of biopharmaceutics at Uppsala University. He currently manages an IMI project entitled OrBiTo, which aims to improve oral drug delivery; controlling a budget of 24.5 MEuro. His research responsibilities and remit are focused on membrane transport and metabolism of drugs/metabolites in the gastrointestinal tract, hepatobiliary system and cancer tissues.

Lennernäs has served as the Principal Investigator in an extensive collaboration with the FDA, University of Michigan and Medical Product Agency of Sweden over the course of several years in which he developed a new guideline for the biopharmaceutics classification system. He has established an extensive and widely used human permeability database.

In addition to his academic achievements, Lennernäs has built an entrepreneurial reputation  by co-founding  several companies including DuoCort Pharma and LIDDS, while investing in a number of patents.